Associate Professor Richard Haynes
Professor of Renal Medicine and Clinical Trials
- MRC Population Health Research Unit Programme Leader: Randomised Trials in Cardiovascular and Metabolic Disease
- MSc in Global Health Science module 8 lead: Clinical Trials and Meta-Analysis
Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Shortly after that he was appointed to the MRC Programme Leader track and he is now Programme Leader in the MRC Population Health Research Unit for the programme in Randomised Trials in Cardiovascular and Metabolic Disease.
Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.
Lamprea-Montealegre JA. et al, (2019), Clin J Am Soc Nephrol
Investigating modifications to participant information materials to improve recruitment into a large randomized trial.
HPS2-THRIVE Collaborative Group None. et al, (2019), Trials, 20
Streamlined mail-based methods for large randomised trials: lessons learnt from the ASCEND study.
Mafham MM. et al, (2019), Diabetologia
Effects of omega−3 fatty acid supplements on arrhythmias
PARISH S. et al, (2019), Circulation
Kidney disease trials for the 21st century: innovations in design and conduct.
Herrington WG. et al, (2019), Nat Rev Nephrol